The North America Gene Expression Analysis Market is witnessing robust growth driven by rapid advancements in genomics research and increasing investments in personalized medicine. With the growing prevalence of chronic diseases and the need for advanced diagnostic solutions, the market is anticipated to expand at a healthy pace through 2035. The market size was valued at USD 1,420 Million in 2025 and is expected to reach USD 3,260 Million by 2035, growing at a CAGR of 7.8% from 2024 to 2035.
The economic impact of tariffs on "North America Gene Expression Analysis Market".
North America Gene Expression Analysis Market Market Growth Drivers
Expansion of Precision Medicine: The increasing focus on precision medicine is a significant driver for gene expression analysis in North America. Companies like Thermo Fisher Scientific are heavily investing in research and development to integrate gene expression profiling into personalized medicine workflows. Such advancements are enabling healthcare providers to create tailored treatment regimens based on individual patient profiles, leading to improved outcomes and fueling market growth.
Growing Oncology Research: The surge in oncology research is another vital driver. With cancer being a leading cause of morbidity and mortality in the region, institutions and market players such as Illumina, Inc. are shifting towards advanced gene expression platforms to identify new biomarkers, therapeutic targets, and predictive models. This increased research activity accelerates product innovation and market adoption.
North America Gene Expression Analysis Market Market Trends
Integration of Artificial Intelligence & Machine Learning: One of the most significant trends is the integration of AI and ML into gene expression data analysis. Companies like Agilent Technologies are leveraging AI-driven platforms to enhance data interpretation, reduce analysis time, and improve the accuracy of diagnostics. These technologies are making high-throughput gene expression analysis more feasible and reliable for large-scale clinical and research applications.
Adoption of Single-cell RNA Sequencing: The adoption of single-cell RNA sequencing techniques is gaining momentum across North America. 10x Genomics has pioneered technologies that enable the resolution of gene expression at the single-cell level, providing deeper insights into cell heterogeneity. This trend is transforming both basic and clinical research landscapes, opening new possibilities in disease mechanism studies and drug development.
North America Gene Expression Analysis Market Market Opportunity
Emerging Applications in Rare Disease Diagnosis: There is a substantial opportunity for growth in rare disease diagnostics utilizing gene expression analysis. Companies such as Qiagen are developing specialized panels and assays to address the unmet needs of this niche segment, paving the way for earlier detection and improved management of rare diseases.
Expansion in Companion Diagnostics: With the FDA emphasizing personalized therapies, the demand for gene expression-based companion diagnostics is set to rise. Major players like Thermo Fisher Scientific are collaborating with pharmaceutical companies to co-develop diagnostic tests that predict patient responses to targeted treatments.
North America Gene Expression Analysis Market Revenue (USD Million), 2020-2035
The market revenue for the North America Gene Expression Analysis Market is projected to showcase consistent growth from 2020 to 2035. The chart demonstrates an upward trend, with revenue increasing from USD 720 Million in 2020 to approximately USD 3,260 Million by 2035. This rise is attributed to technological advancements, the growing application of gene expression profiling in drug development, and an increase in research funding. The plateau in earlier years transitions into a steeper growth curve as more investments and novel technologies enter the market, underlining the sector's expanding role in personalized medicine, diagnostics, and disease research.
North America Gene Expression Analysis Market by Regions Share (%), 2025
The pie chart for 2025 illustrates the regional distribution of the North America Gene Expression Analysis Market. The United States dominates the market, representing 77% share due to significant investments in genomics research, advanced healthcare infrastructure, and extensive presence of key players. Canada follows with a 15% share, propelled by rising research activity and government initiatives. Mexico captures 5%, driven by increasing awareness and investment, while Other North American countries together account for 3%. This regional split highlights the central role of the U.S. in driving market expansion within North America.
Recent Developments in North America Gene Expression Analysis Market
In April 2024, Illumina Inc. launched a new high-throughput sequencing platform designed to accelerate gene expression studies for clinical diagnostics and research. The new system increases data accuracy and reduces costs, catering to both large-scale academic institutions and pharmaceutical companies. This launch is expected to strengthen Illumina's market position and further expand the accessibility of comprehensive gene expression analysis.
In May 2024, Thermo Fisher Scientific announced a strategic partnership with leading biopharma company Pfizer to co-develop gene expression-based companion diagnostics for cancer therapeutics. The collaboration is aimed at enhancing precision in treatment selection for oncology patients, utilizing Thermo Fisher’s advanced gene panel technologies to predict therapy response rates.
In March 2024, Agilent Technologies unveiled its latest artificial intelligence-powered software suite for gene expression data analysis. The new solution provides automated data interpretation, enabling faster turnaround for clinical decision-making and research studies. Agilent’s move underscores the rapid digitalization of gene expression workflows in the North American market.
Press Releases